Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
Research grant aiming to understand schizophrenia and related disorders in mid- to late-life for improved prevention and treatment strategies.
Funder: National Institutes of Health
Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision)
Funding Amounts: No budget cap; budgets must reflect actual project needs. Maximum project period: 5 years.
Summary: Supports translational research to understand the emergence and trajectory of schizophrenia and related disorders in mid- to late-life, identifying targets for prevention and treatment.
Key Information: Applications must focus on populations aged 35 and older; projects evaluating safety/efficacy or targeting <35 years are not responsive.
Description
This NIH opportunity (R01, Clinical Trial Optional) seeks to advance translational research on the mechanisms underlying the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life (defined as age 35 and above). The goal is to identify neurobiological, behavioral, psychosocial, and environmental mechanisms that can inform future prevention and intervention strategies for this population, which is underrepresented in current research despite high disease burden.
Research may address first-episode psychosis in mid- to late-life, mechanisms of cognitive and functional decline, risk of dementia, accelerated biological aging, social determinants of health, resilience, and recovery. Projects should integrate multiple levels of analysis and may use innovative methods, but must include human subjects and focus on the specified age group.
